November 27, 2012
Investors have recently focused on the NCE status for Amarin's (Nasdaq: AMRN ) triglyceride-lowering drug Vascepa and potential suitors for the company, but many might be overlooking a topic that is essential to the future of this biotech stock: patents.
A cascade of patents protecting Vascepa from generic competitors has been rolling in lately, and Amarin is keen on obtaining more IP for its flagship product. In this video, health-care analysts Max Macaluso and Brenton Flynn talk about the drug's latest patents, and discuss why they are so vital for Amarin today.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Max's premium research report. Click here now to keep reading.